You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 興齊眼藥(300573.SZ)漲5.39% 定增方案出台 有望加快公司發展腳步
格隆匯 09-23 13:44
格隆匯9月23日丨興齊眼藥(300573.SZ)漲5.39%,報140.5元,總市值115.7億元。公司本月發佈2020年度向特定對象發行A股股票預案,向特定對象發行股票募集資金不超過8億元,扣除發行費用後的募集資金淨額將用於單劑量生產線建設項目、研發中心建設及新藥研發項目、補充流動資金。安信證券發佈研報認為,本次定增一方面補充了核心產品環孢素滴眼液未來的產能需求,另一方面提升了低濃度阿托品等重磅研發管線的研發效率,有利於公司在眼科領域深耕細作。國盛證券研報稱,定增將為阿托品滴眼液2.4類新藥臨牀提供充足資金,預計公司阿托品滴眼液有望2023年底至2024年獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account